Overview
AMRN market data
Price History
AMRN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AMRN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dLBenzinga · Jun 30, 2026, 8:20 PM
Hikma comments on Supreme Court of the United States' unanimous decision in favour of HikmaBenzinga · Jun 4, 2026, 10:15 PM
U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By AmarinBenzinga · Jun 4, 2026, 2:15 PM
Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular RiskBenzinga · May 27, 2026, 12:03 PM